Candriam S.C.A. Revance Therapeutics, Inc. Transaction History

Candriam S.C.A.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Oct 19, 2020	SELL	$23.23 - $34.3 $1.05 Million - $1.54 Million	-45,000 Closed	0 $0
Q2 2020 Jul 23, 2020	SELL	$12.6 - $26.55 $2.14 Million - $4.51 Million	-170,000 Reduced 79.07%	45,000 $1.1 Million
Q4 2019 Jan 21, 2020	SELL	$11.66 - $20.15 $256,520 - $443,299	-22,000 Reduced 9.28%	215,000 $3,000
Q4 2018 Feb 14, 2019	BUY	$18.06 - $24.96 $1.19 Million - $1.65 Million	66,000 Added 38.6%	237,000 $4.77 Million
Q1 2018 May 09, 2018	BUY	$29.15 - $37.4 $583,000 - $748,000	20,000 Added 13.25%	171,000 $5.27 Million
Q4 2017 Feb 07, 2018	BUY	$24.55 - $36.3 $368,250 - $544,500	15,000 Added 11.03%	151,000 $5.4 Million
Q3 2017 Nov 03, 2017	BUY	$22.55 - $28.1 $3.07 Million - $3.82 Million	136,000	136,000 $3.75 Million

230

81.5M

617K

870K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.